
Lumiera Health Inc.

**Investor Presentation** 



This presentation of LUMIER HEALTH Inc. ( the "Company") is for information only and shall not constitute an offer to buy, sell, issue or subscriber for, or the solicitation of an offer to buy, sell, issue or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, and under no circumstances is it to be construed as a prospectus or advertisement or public offering of the securities.

This presentation is confidential and is being provided to you solely for your information and may not be reproduced, in whole or in part, in any form or forwarded or further distributed to any other person. Any forwarding, distribution or reproduction of this presentation, in whole or in part, is unauthorized. By accepting and reviewing this presentation, you acknowledge and agree (i) to maintain the confidentiality of this presentation and the information contained herein, (ii) to protect such information in the same manner you protect your own confidential information, which shall be at least a reasonable standard of care, and (iii) to not utilize any of the information contained herein except to assist with your evaluation of the Company. This version of the presentation supersedes and replaces any and all versions of this presentation previously provided to you.

The information contained in this document (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable fully and accurately to evaluate an investment in the Company (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company and (d) is based on publicly available information, internally developed data and other sources.

Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The Company disclaims and excludes all liability (to the extent permitted by law) for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances.

An investment in the Company is speculative and involves substantial risk and is only suitable for investors that understand the potential consequences and are able to bear the risk of losing their entire investment. Investors should consider the following risks, in addition to many others, and consult with their own legal, tax and financial advisors with respect to all such risks before making an investment."

The Company is in the early stage of development and has a limited operational history, making it difficult to accurately predict business operations.

Historical statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided by the Company. In particular

historical results of the Company should not be taken as a representation that such trends will be replicated in the future. No statement in this document is intended to be nor may be construed as a profit forecast.


The information contained in this presentation is not directed to persons or entities resident in the United States and does not constitute an offer or solicitation by anyone in the United States or in any other jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation, unless otherwise exempt from United States securities legislation. There are certain risks inherent in an investment in the securities of the Company that prospective investors should carefully consider before investing in the securities of the Company.

#### Forward Looking Statements

Certain statements contained in this presentation constitute forward-looking information within the meaning of applicable securities laws. Forward-looking information may relate to the Company's future outlook and anticipated events or results and may include statements regarding the financial position, business strategy, budgets, projected costs, capital expenditures, financial results, plans and objectives of or involving the Company. Some of the specific forward-looking statements in this presentation include, but are not limited to, statements with respect to the forecasted financial results of the Company for the periods set out under "LUMIERA's P&L Summary". Statements containing the words "believe." "expect." "intend," "should," "seek," "anticipate," "will," "positioned," "project," "risk," "plan," "may," "estimate" or, in each case, their negative and words of similar meaning are forward-looking statements. Although the forward-looking statements contained in this presentation are based upon assumptions that management of the Company believes are reasonable based on information currently available to management, there can be no assurance that actual results will be consistent with these forward-looking statements. By their nature, forward-looking statements are inherently uncertain, are subject to risk and are based on assumptions, many of which are beyond the Company's control and may cause the Company's or the industry's actual results, performance, achievements, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. The reader is further cautioned that the preparation of the financial forecast included in this presentation requires management of the Company to make certain assumptions, judgments and estimates that affect the forecast of financial results, including assets, revenues, liabilities and expenses. These estimates may change, having either a negative or positive effect on actual results as further information becomes available, and as the economic environment changes. These forward-looking statements are made as of the date of this presentation, and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. Investors are cautioned that forward-looking statements are not guarantees of future performance. Actual results could differ materially from those currently anticipated due to a number of factors and risks.

LUMIERA HEALTH Inc. expressly disclaims any intention or obligation to update or revise any forward-looking information and statements, whether as a result of new information, events or otherwise, except in accordance with applicable securities laws.

**Our Values** 





**Our Mission** 

**Our Vision** 

To help people feel better each day with innovative Natural Health Products

Become a leader in the Natural Health Product industry through:

- Excellence in Distribution
  Experts in efficiently expanding Retail + Online distribution
- 2 Efficient Consumer Acquisition
  Introduce & educate for trial, trial, trial of products/brands
- Acquiring Natural Health businesses/brands

  Evaluators and aggregators of value assets

Who we are



• Founded in 2018

• Ticker: NHP.V

- Lumiera provides consumers with natural innovative solutions in high growth categories (pain relief, sleep-aids, etc.)
- Owner of over 47 licenses and Natural Product Numbers (NPN)
- Focus on soft innovation and acquisition no R&D or clinical trial costs and risks
- Fast revenue growth anticipated



# Natural Health Products that Meet Canadians' Health and Wellness Needs

# awaye Pain Relief

- New generation, clinically tested topical pain relief brand.
- Launched in April 2021.

# **BAZZZICS** Sleep Aids

- The innovative new line of natural sleep-aids available in three formulas that can be combined to address specific sleeping needs.
- Launched in December 2020.

# Holizen Tonics & Supplements

- A wide range of natural tonics and supplements that fit into your everyday life.
- Unique formulations that use the finest quality, naturally-sourced ingredients
- In distribution in Quebec for 20 years.

Intro to Awaye™ Pain Relief Cream



# awaye

#### A New Disruptive Product launched April 2021:

- First topical product that acts on the endocannabinoid system without the use of cannabis (no regulatory hurdles)
- Key Benefits: Reduces inflammation, no side effects, non-addictive (dependency and side effects are the #1 concern re: pain management drugs that are consumed orally)



#### **Growth Plans for 2022 & 2023:**

- Launch in Retail Channels across Canada with trade marketing support to drive trial
- Launch in Retail Channels in the US Tri-State area and list product on Amazon.com (important revenue opportunity)
- Launch in Vietnam market scheduled for early 2023
- Pursue distribution and licensing opportunities in Europe & Africa
- Continue building social presence to accelerate online sales (Amazon, Well.ca, Awaye.ca)
- Soft Innovation Product line extensions:
  - Awaye™ Sport with Menthol
  - Awaye™ Arnica

Intro to BAZZZICS
Sleep Aids



# **BAZZZICS**

#### A New Disruptive Product launched Q4 2020:

- An innovative line of 3 Natural Sleep Aid products that can be customized to your individual sleeping needs
- Key Benefits: Natural, no side effects, non-addictive (dependency is the #1 concern/barrier to sleep aid use)
- Unique formulas containing extracts of California Poppy, Passiflora, Skullcap and Lemon Balm
- Sold in environmentally friendly packaging

## Growth plans for 2022 and 2023:

- Continue to acquire Direct-To-Consumer (DTC) buyers (launched on Amazon March 2022)
- Continue to Build Social presence to drive trial and maximize online conversions
- Continue to expand National Distribution, started 2022 with only 80 stores; huge retail distribution opportunity!
- Pursue distribution opportunities in Northeastern US and launch on Amazon.com
- Focus on In-Store Education with retailers and in-house experts
- New 10-count pack size (launch April 2022) hitting high volume price partition



Intro to Holizen
Tonics & Supplements







#### **LUMIERA's Base Business: Holizen Herbal Tonics & Supplements:**

- HOLIZEN has been in distribution in Quebec for nearly 20 years
- Strong Brand equity and loyal consumer base
- Broad range of products, with top 5 SKUs accounting for 65% of sales
- High awareness in QC Natural Stores and amongst category users

### **Turn around complete and now driving Growth:**

- Current execution focus:
  - Expanding QC distribution via new Retail Sales Team
  - Increasing Trial/purchase through 'Education/Detail Sales Team'
  - Launch new Brand strategy and Website to grow online sales
  - Building Social presence and investing in Digital media to drive trial and conversion
  - Consistent source of revenues
- Back half 2022 and 2023 focus:
  - Distribution: increase in Key Accounts across new Canadian markets
  - Innovation: Expand portfolio with line extensions of historically strong top selling SKUs/products



**Key Progress Updates** 

## Progress since arrival of New Management in Q2 2021

## > Rapid impact on revenues

- Lumiera's new management team turned around a declining Holizen business, launched BAZZZICS, and Awaye™
- Refocused on core business and successful products
- Increased sales through retail distribution and online recruitment

## > Net Sales Increase - Year over year:

Q4 2021 Q1 2022 +30% +26%





## Progress since arrival of New Management in Q2 2021

## > Financial Impact:

- Reduced recurrent costs by more than \$300K (on a yearly basis)
- Reduced monthly net loss by \$60K
- Mapped out path to profitability by Q1 2023

### > Diversification of Lumiera's revenues

- Lumiera is now a multi brand company with a wide stream of revenues
- Our focus is growing via distribution and Direct-to-Consumer acquisition






**Key Progress Updates** 

# **Increased Online Distribution & Sales**









Great reviews – consumers love our products!



Maximizing
Long Term
Shareholder Value

# Why Invest?

## **Strong Foundation**

- Turnaround was completed in 2021 Now let the fun begin!
- Rapid revenue growth (forecasted 100% YOY, 2021 vs 2022)
- Improved profitability through product margin mix, average order value and cost efficiencies
- Improve cost structure through economies of scale and grow operating leverage through volume growth



## **Growing Markets & Big Opportunities**

- Tail-wind growth categories: Natural Health Product category is projected to grow double digits to 2027
- Awaye: Broker/Distribution agreements have been signed for sales in US and Vietnam. They are also licensing opportunities in Europe and Africa.
- Bazzzics: According to published reports, "Western and Asian consumers are seeking more and more natural sleeping aids to face sleep disturbances. Sleep aids should be one of the fastest growing categories in dietary supplement in the coming years."



Maximizing Long Term Shareholder Value



# **Positioned to Win**

- People are looking for NATURAL alternatives for their medical and wellness needs
- Pure commercial Brand play with focus on soft innovation and acquisitions (No R&D financial risks)
- 2 pivotal launches completed in 2021, both in high growth categories (Pain relief & Sleep Aids)
- Huge addressable market for Awaye<sup>™</sup> in 2022: 465M people!
- New structure fully operational since Q4 2021
- Turning EBITDA positive shortly



#### Leadership

# **An Experienced Team that delivers**

#### **Management**

#### Carlos Ponce CEO & Director

- 25 years experience in Brand marketing commercialization in Regulated Categories
- Cross-industry background; pharmaceuticals, OTC, Natural Health Products, Food & Beverage, Financial Services

#### Simon Castonguay, CPA, CA CFO & Director

- +12 years experience in banking, external audits, taxation, business development and risk management
- Category & industry expertise; Finance, Health, Manufacturing, Food & Beverage, non-profit and public sector
- CPA, CA Member of the Canadian Chartered Professional Accountants

#### **Independent Board Members**

#### Kevin Cole Chairman

- +20 years experience building teams that transform small brands & businesses into Global leaders
- Category & industry expertise; OTC, NHP (GSK CH), Consumables (MARS) and current CEO of STEM Animal Health

#### Marie Belanger Director

- +20 years Consumer-Packaged Goods experience across Sales, Marketing and Operations
- Category & industry expertise; Chief Operating Officer for Santé Naturelle (AG) Ltée, plus roles at Phytoderm and Proctor & Gamble

#### Louis Doyle Director

- +30 years experience focused primarily on capital markets and public companies
- Former VP of TSX Venture Exchange for more than 16 years.
- Held directorship roles with publicly traded companies, the latest of which: Abitibi Royalties Inc.

#### Jacqueline Khayat Director

- +20 years experience of developing and launching consumer products brand in the US and other markets
- Category & industry expertise; sales, business development, strategy and M&A in the health and wellness

# lumıera

Lumiera.ca

